Impact of exacerbations on the clinical course of chronic obstructive pulmonary disease;Impacto de las exacerbaciones en la evolución de la EPOC

Revista Clinica Espanola

Volumn 211, Issue SUPPL. 2, 2011, Pages 3-12

  Soler Cataluna J J ^a   Martinez Garcia M A ^a   Catalan Serra P ^a   Roman Sanchez P ^a  

^a HOSPITAL GENERAL DE REQUENA   (Spain)

Author keywords

COPD; Exacerbation; Phenotype

Indexed keywords

BRONCHIECTASIS; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; MORBIDITY; MORTALITY; PHENOTYPE; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; WORKLOAD;

EID: 79956265161     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(11)70006-6     Document Type: Article

References (65)

1. Fletcher CM, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. New York, Toronto: Oxford University Press; 1976.
2. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, et al. The costs of exacerbatons in chronic obstructive pulmonary disease (COPD). Respir Med. 2002;96:700-8.
3. Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med. 2003; 97:S3-4.
4. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med.1998;157:1418-22.
5. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698-702. (Pubitemid 38618138)
6. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52. (Pubitemid 35178607)
7. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:358-64. (Pubitemid 32778199)
8. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925-31. (Pubitemid 41598207)
9. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 2007;176;532-55. (Pubitemid 47403272)
10. Han MK, Agustí A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med. 2010;182:598-604.
11. Tashkin DP. Frequent exacerbations of chronic obstructive pulmonary disease- a distinct phenotype? N Engl J Med. 2010;16:1183-4.
12. Hurst JR, Wedzicha JA. What is (and what is not) a COPD exacerbation: thoughs from the new GOLD guidelines. Thorax. 2007;62:198-9. (Pubitemid 46579796)
13. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177:396-401. (Pubitemid 351317582)
14. Tsoumakidou M, Siafakas NM. Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations. Respiratory Research. 2006;7:80.
15. Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995-2004. (Pubitemid 41507533)
16. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867-74. (Pubitemid 44564786)
17. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL; on behalf of the EOLO group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration. 2000;67:495-501.
18. Hurst JR, Vestbo J, Anzeto A, Locantore N, Müllerova H, Tal- Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-38.
19. Soler-Cataluña JJ, Rodríguez-Roisín R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious? COPD. 2010;7:276-84.
20. Soler-Cataluña JJ, Martínez-García MA, Sánchez L, Perpiñá M, Román P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103:692-9.
21. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, España PP, et al. Predictors of mortality in patients with stable COPD. J Gen Intern Med. 2008;23:1829-34.
22. Alfageme I, Reyes N, Merino M, Reina A, Gallego J, Lima J, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron Respir Dis. 2010;7:135-45.
23. Soler JJ, Sánchez L, Latorre M, Alamar J, Román P, Perpiñá M. The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization. Arch Bronconeumol. 2001;37:375-81. (Pubitemid 33682760)
24. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, et al. Acute exaerbation of COPD: factors associated with poor outcome. Chest. 2000;117:662-71. (Pubitemid 30152203)
25. García-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58:100-5. (Pubitemid 36182995)
26. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131:20-8. (Pubitemid 46122970)
27. BhowmiK A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114-20. (Pubitemid 30245950)
28. Patel IS, Seemungal TAR, Wiks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759-64. (Pubitemid 34984972)
29. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975-82.
30. Soler JJ, Sánchez L, Román P, Martínez MA, Perpiñá M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir Med. 2004;98:318-29. (Pubitemid 38443691)
31. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J. 2008;32:53-60.
32. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J. 1997;10:417-23. (Pubitemid 27063862)
33. Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008;63:951-5.
34. Takabatake N, Shibata Y, Abe S, Wada T, Machiya JI, Igarashi A, et al. A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:875-85. (Pubitemid 44564787)
35. Yang IA, Seeney SL, Wolter JM, Anders EM, McCormack JG, Tunnicliffe AM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes and Immunity. 2003;4:269-74. (Pubitemid 39562126)
36. Foreman MG, DeMeo DL, Hersh CP, Carey VJ, Fan VS, Reilly JJ, et al. Polymorphic variation in surfactant protein B is associated with COPD exacerbations. Eur Respir J. 2008;32:938-44.
37. O'Donnell DE, Parker CM. COPD exacerbations. Pathophysiology. Thorax. 2006;61:354-61.
38. Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiologic changes during symptom recovery from moderate exacerbation of COPD. Eur Respir J. 2005;26:420-8. (Pubitemid 41264203)
39. Groenewegen KH, Dentener MA, Wouters EFM. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. Respir Med. 2007;101:2409-15. (Pubitemid 47471393)
40. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient's perception of exacerbation of COPD - the PERCEIVE study. Respir Med. 2007;101:453-60. (Pubitemid 46196335)
41. Kessler R, Stähl E, Vogelmeir C, Haughmey J, Trudeau E, Löfdahl C-G, et al. Patient undestainding, detection, and experience of COPD exacerbations. An observational, interview-based study. Chest. 2006;130:133-42.
42. Miravitlles M, Ferrer M, Pont A, Zalacaín R, Álvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387-95. (Pubitemid 38624744)
43. Soler JJ, Sánchez L, Román P, Martínez MA, Perpiñá M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Resp Med. 2004;98:318-29. (Pubitemid 38443691)
44. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J. 2007;30:907-13. (Pubitemid 351194794)
45. Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101:1305-12. (Pubitemid 46667662)
46. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131:696-704. (Pubitemid 46446859)
47. Wilkinson TMA, Donaldson GC, Johnston SL, Openshay PJM, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:871-6.
48. Hurst JR, Perera W, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:71-8. (Pubitemid 43069790)
49. Donaldson GC, Hurst JR, Smith CJ, Hubbar RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of chronic obstructive pulmonary disease. Chest. 2010;137:1091-7.
50. Brekke PH, Olmland T, Holmedadl SH, Smith P, Soyseth V. Troponin T elevation and long-term mortality afther chronic obstructive pulmonary disease exacerbation. Eur Respir J. 2008;31:563-70.
51. Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V. Determinants of cardiac troponin T elevation in COPD exacerbation - a cross-sectional study. BMC Pulm Med. 2009;9:35.
52. Laukides S, Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration. 1996;63:170-3. (Pubitemid 26122025)
53. Antonelli R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800. (Pubitemid 28052790)
54. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(1):CD001288.
55. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, et al. Hyperglycaemia is associated with poor outcomes in patient admited to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284-9.
56. Marquis K, Maltais F, Duguay V, Bezeau AM, Leblanc J, Jobin J, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. Cardipulm Rehabil. 2005;25:226-32. (Pubitemid 41153761)
57. Watz H, Waschki B, Kirsten A, Müller KC, Krestschmar G, Meyer T, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136:1039-46.
58. Lam KB, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J. 2010;35:317-23.
59. Küpeli E, Ulubay G, Ulasli SS, Sahin T, Erayman Z, Gürsoy A. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocr. 2010;38:76-82.
60. Girón R, Matesanz C, García-Río F, De Santiago E, Macha A, Rodríguez-Salvanés F, et al. Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann Nutr Metab. 2009;54:52-8.
61. Hopkinson NS, Tennant RC, Dayer MJ, Swallow EB, Hansel TT, Moxham J, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Resp Res. 2007;8:25.
62. Connors AF, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med. 1996;154:959-67.
63. Almagro P, Calbo E, Ochoa de Echagüen A, Barreiro B, Quintana S, Heredia JL, et al. Mortality after hospitalization for COPD. Chest. 2002;121:1441-8. (Pubitemid 34499653)
64. Groenewegen KH, Schols AMWJ, Wouters E. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459-67. (Pubitemid 37000120)
65. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am J Respir Crit Care Med. 2009;180:1189-95.